- Subgroup Analysis by Ki-67 and Baseline CgA of the Randomized, Placebo-Controlled Phase 3 Study of Surufatinib in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors (SANET-p)Yu, Xianjun; Xu, Jianming; Shen, Lin; Bai, Chunmei; Li, Jie; Zhou, Zhiwei; Li, Zhiping; Li, Enxiao; Yuan, Xianglin; Chi, Yihebali; Yin, Yongmei; Lou, Wenhui; Xu, Nong; Bai, Yuxian; Zhang, Tao; Xiu, Dianrong; Wang, Xiuwen; Guan, Sha; Fan, Songhua; Su, Weiguo
- Molecular-Genetic Features of Pancreatic Neuroendocrine TumorsO. I., Kit; D. Yu., Gvaldin; V. S., Trifanov; E. N., Kolesnikov; N. N., TimoshkinaRUSSIAN JOURNAL OF GENETICS, 2020, 56(2): 142-158.
- A case of pancreatic neuroendocrine tumor in a patient with neurofibromatosis-1Takeshi, Nishi; Yasunari, Kawabata; Youko, Hari; Hiroshi, Imaoka; Noriyoshi, Ishikawa; Seiji, Yano; Riruke, Maruyama; Yoshitsugu, TajimaWorld Journal of Surgical Oncology, 2012, 10(1): 153.被引 7
期刊论文
The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020)
22阅读
